Gao Xiaoyu, Liu Feng, Wang Gang, Gao Yu, Suyalatu Xin
Department of Orthopedics, Ordos Central Hospital, Ordos, Inner Mongolia Autonomous Region 017000, P.R. China.
Exp Ther Med. 2023 Dec 27;27(2):77. doi: 10.3892/etm.2023.12365. eCollection 2024 Feb.
The present study aimed to investigate the serum levels of caspase-1 in patients with high-energy pilon fractures, and its correlation with prognosis and clinical results. In this prospective study, 136 patients with high-energy pilon fractures who were treated with a locking plate combined with ankle arthroscopy from July 2015 to July 2020 were included. The treatment efficacy was evaluated according to the Mazur ankle function score. Serum caspase-1, interleukin (IL)-6, IL-1β and C-reactive protein (CRP) levels were measured using enzyme-linked immunosorbent assay. Reverse transcription-quantitative PCR was used to measure the mRNA expression of caspase-1. Additionally, demographic data and clinical characteristics, such as sex, age, intraoperative blood loss, fracture healing time, fracture classification and complications were collected and analyzed. The study revealed that the intraoperative blood loss, proportion of Ruedi-Allgower III and the serum levels of caspase-1 in the poor prognosis group were significantly higher compared with those in the good prognosis group. Additionally, patients with high-energy pilon fractures in the poor prognosis group exhibited significantly higher levels of caspase-1 and IL-1β serum levels at all time points in contrast to those in the good prognosis group. Spearman's analysis revealed a significant association between caspase-1, IL-1β levels and Mazur scores. Furthermore, caspase-1 could serve as a potential diagnostic biomarker for poor prognosis of patients with high-energy pilon fractures. Caspase-1, IL-1β, intraoperative blood loss and Ruedi-Allgower grade were the risk factors for poor prognosis in patients with high-energy pilon fractures. In summary, this study demonstrated that serum caspase-1 levels were progressively reduced during the treatment of high-energy pilon fractures patients and prominently lowered in those with a favorable prognosis. These findings could provide novel targets and a comprehensive approach to protecting patients with high-energy pilon fractures.
本研究旨在探讨高能Pilon骨折患者血清半胱天冬酶-1水平及其与预后和临床结果的相关性。在这项前瞻性研究中,纳入了2015年7月至2020年7月期间采用锁定钢板联合踝关节镜治疗的136例高能Pilon骨折患者。根据Mazur踝关节功能评分评估治疗效果。采用酶联免疫吸附测定法检测血清半胱天冬酶-1、白细胞介素(IL)-6、IL-1β和C反应蛋白(CRP)水平。采用逆转录定量PCR检测半胱天冬酶-1的mRNA表达。此外,收集并分析人口统计学数据和临床特征,如性别、年龄、术中出血量、骨折愈合时间、骨折分类和并发症。研究显示,预后不良组的术中出血量、Ruedi-Allgower III型比例和血清半胱天冬酶-1水平显著高于预后良好组。此外,与预后良好组相比,预后不良组的高能Pilon骨折患者在所有时间点的半胱天冬酶-1和IL-1β血清水平均显著升高。Spearman分析显示半胱天冬酶-1、IL-1β水平与Mazur评分之间存在显著关联。此外,半胱天冬酶-1可作为高能Pilon骨折患者预后不良的潜在诊断生物标志物。半胱天冬酶-1、IL-1β、术中出血量和Ruedi-Allgower分级是高能Pilon骨折患者预后不良的危险因素。总之,本研究表明,在高能Pilon骨折患者的治疗过程中,血清半胱天冬酶-1水平逐渐降低,预后良好的患者降低更为显著。这些发现可为保护高能Pilon骨折患者提供新的靶点和综合方法。